# Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026
Canonical URL: https://biopharmsignal.com/news/SANA/sana-biotechnology-announces-symposium-presentation-at-the-european-association--26e086a1
Ticker: SANA
Company: Sana Biotechnology
Source: Sana Biotechnology
Published: 2026-07-01 13:00 EST
Original Source URL: https://ir.sana.com/news-releases/news-release-details/sana-biotechnology-announces-symposium-presentation-european
## Summary

SEATTLE, July 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation highlighting clinical data from an investigator-sponsored, first-in-human study

## Article Body
SEATTLE, July 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation highlighting clinical data from an investigator-sponsored, first-in-human study
## Recent Company News
- 2026-07-01 13:00 EST — [Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026](https://biopharmsignal.com/news/SANA/sana-biotechnology-announces-symposium-presentation-at-the-european-association--26e086a1) — Source: Sana Biotechnology
- 2026-06-25 13:46 EST — [Sana Biotechnology to Present at June 2026 Investor Conferences](https://biopharmsignal.com/news/SANA/sana-biotechnology-to-present-at-june-2026-investor-conferences) — Source: Sana Biotechnology
- 2026-06-25 13:46 EST — [Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility](https://biopharmsignal.com/news/SANA/sana-biotechnology-announces-sale-of-approximately-69-million-of-shares-through-its-at-the-market-atm-facility) — Source: Sana Biotechnology
- 2026-06-25 13:46 EST — [Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs](https://biopharmsignal.com/news/SANA/sana-biotechnology-presents-preclinical-data-for-in-vivo-car-t-cell-therapy-sg293-surrogate-demonstrating-cell-specific-delivery-potent-car-t-cell-generation-and-deep-b-cell-depletion-in-nhps) — Source: Sana Biotechnology
- 2026-06-25 13:46 EST — [Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/SANA/sana-biotechnology-reports-first-quarter-2026-financial-results-and-business-updates) — Source: Sana Biotechnology
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)